Dr. John Cush
@rheumnow.bsky.social
Know-it-Now. Info on RA, Stills disease, Lupus, Gout, Pregnancy, Spondylitis, Psoriasis, Drug Safety, Rheumatology Research, Medical Education & Drug Evaluation
Rheumnow.com
Rheumnow.com
Chronic pain may dramatically raise your blood pressure
Widespread chronic pain may stealthily drive up blood pressure, partly through its ties to depression and inflammation.
rheumnow.com/news/chronic...
Widespread chronic pain may stealthily drive up blood pressure, partly through its ties to depression and inflammation.
rheumnow.com/news/chronic...
November 28, 2025 at 5:00 PM
Chronic pain may dramatically raise your blood pressure
Widespread chronic pain may stealthily drive up blood pressure, partly through its ties to depression and inflammation.
rheumnow.com/news/chronic...
Widespread chronic pain may stealthily drive up blood pressure, partly through its ties to depression and inflammation.
rheumnow.com/news/chronic...
2023 National Health Interview Survey studied arthritis-attributable work limitations in adults (18-64 yrs) - it was 38.8% (same as 2019). AAWL was higher in Hispanics (50%), American Indian/Alaska Natives (56%), & disabled (62%), & veterans (52%) acrjournals.onlinelibrary.wiley.com/doi/pdf/10.1...
November 27, 2025 at 3:02 PM
2023 National Health Interview Survey studied arthritis-attributable work limitations in adults (18-64 yrs) - it was 38.8% (same as 2019). AAWL was higher in Hispanics (50%), American Indian/Alaska Natives (56%), & disabled (62%), & veterans (52%) acrjournals.onlinelibrary.wiley.com/doi/pdf/10.1...
CorEvitas ional registry of 3,696 w/ psoriatic arthritis (no hx of CV eents), followed for mean 3.7 yrs, showed that Dactylitis & enthesitis didnt predict future CV events. But Dactylitis & enthesitis & Synovitis were all significantly interrelated. Cureus 17(11): e97377. doi:10.7759/cureus.97377
November 26, 2025 at 11:44 PM
CorEvitas ional registry of 3,696 w/ psoriatic arthritis (no hx of CV eents), followed for mean 3.7 yrs, showed that Dactylitis & enthesitis didnt predict future CV events. But Dactylitis & enthesitis & Synovitis were all significantly interrelated. Cureus 17(11): e97377. doi:10.7759/cureus.97377
Tuesday Nite Rheumatology (on 11.18.25)
Replay of RheumNow Live 2025 - Spondyloarthritis
Replay of RheumNow Live 2025 - Spondyloarthritis
November 26, 2025 at 5:02 PM
Tuesday Nite Rheumatology (on 11.18.25)
Replay of RheumNow Live 2025 - Spondyloarthritis
Replay of RheumNow Live 2025 - Spondyloarthritis
Partial vs Total Knee Replacement: Is One Superior?
Patients with OA primarily affecting only one knee joint compartment did just as well with partial knee replacement (PKR) as with total arthroplasty after 10 years in a randomized trial -- and maybe a little bit better.
buff.ly/T6Bscs9
Patients with OA primarily affecting only one knee joint compartment did just as well with partial knee replacement (PKR) as with total arthroplasty after 10 years in a randomized trial -- and maybe a little bit better.
buff.ly/T6Bscs9
November 26, 2025 at 4:00 PM
Partial vs Total Knee Replacement: Is One Superior?
Patients with OA primarily affecting only one knee joint compartment did just as well with partial knee replacement (PKR) as with total arthroplasty after 10 years in a randomized trial -- and maybe a little bit better.
buff.ly/T6Bscs9
Patients with OA primarily affecting only one knee joint compartment did just as well with partial knee replacement (PKR) as with total arthroplasty after 10 years in a randomized trial -- and maybe a little bit better.
buff.ly/T6Bscs9
Retrospective study of 39 pts w/ MDA5 + DM-ILD Rx w baricitinib. 31 (79.5%) had improvement in Gottron’s, heliotrope, dyspnea, HRCT score, ferritin, LDH, steroid dose & 6 mo survival (87% vs. 70%, p = 0.047). arthritis-research.biomedcentral.com/articles/10....
November 24, 2025 at 8:53 PM
Retrospective study of 39 pts w/ MDA5 + DM-ILD Rx w baricitinib. 31 (79.5%) had improvement in Gottron’s, heliotrope, dyspnea, HRCT score, ferritin, LDH, steroid dose & 6 mo survival (87% vs. 70%, p = 0.047). arthritis-research.biomedcentral.com/articles/10....
Vitamin D and Lupus Outcomes (11.21.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.
rheumnow.com/news/vitamin...
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.
rheumnow.com/news/vitamin...
November 24, 2025 at 8:01 PM
Vitamin D and Lupus Outcomes (11.21.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.
rheumnow.com/news/vitamin...
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.
rheumnow.com/news/vitamin...
ILD in Patients with Connective Tissue Disease
Dr. Janet Pope reports on abstract 0154 (Incidence and Prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-ILD) in the United States) at #ACR25.
rheumnow.com/video/ild-pa...
Dr. Janet Pope reports on abstract 0154 (Incidence and Prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-ILD) in the United States) at #ACR25.
rheumnow.com/video/ild-pa...
November 24, 2025 at 7:00 PM
ILD in Patients with Connective Tissue Disease
Dr. Janet Pope reports on abstract 0154 (Incidence and Prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-ILD) in the United States) at #ACR25.
rheumnow.com/video/ild-pa...
Dr. Janet Pope reports on abstract 0154 (Incidence and Prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-ILD) in the United States) at #ACR25.
rheumnow.com/video/ild-pa...
RNL 25 Replay: Spondyloarthritis
Enjoy these excerpts from the RNL 2025 meeting, and join us for RNL 2026 in Dallas, TX - registration is now open! Visit rheumnow.live for complete details.
rheumnow.com/video/rnl-25...
Enjoy these excerpts from the RNL 2025 meeting, and join us for RNL 2026 in Dallas, TX - registration is now open! Visit rheumnow.live for complete details.
rheumnow.com/video/rnl-25...
November 24, 2025 at 5:02 PM
RNL 25 Replay: Spondyloarthritis
Enjoy these excerpts from the RNL 2025 meeting, and join us for RNL 2026 in Dallas, TX - registration is now open! Visit rheumnow.live for complete details.
rheumnow.com/video/rnl-25...
Enjoy these excerpts from the RNL 2025 meeting, and join us for RNL 2026 in Dallas, TX - registration is now open! Visit rheumnow.live for complete details.
rheumnow.com/video/rnl-25...
Organ Involvement with Behçet’s
A review of patient data from the International AutoInflammatory Disease Alliance (AIDA) Network registry identifying those with mucocutaneous Behçet’s disease (BD) may progres to major organ involvement (MOI)m especially at later stages.
buff.ly/7BatMxI
A review of patient data from the International AutoInflammatory Disease Alliance (AIDA) Network registry identifying those with mucocutaneous Behçet’s disease (BD) may progres to major organ involvement (MOI)m especially at later stages.
buff.ly/7BatMxI
November 24, 2025 at 4:00 PM
Organ Involvement with Behçet’s
A review of patient data from the International AutoInflammatory Disease Alliance (AIDA) Network registry identifying those with mucocutaneous Behçet’s disease (BD) may progres to major organ involvement (MOI)m especially at later stages.
buff.ly/7BatMxI
A review of patient data from the International AutoInflammatory Disease Alliance (AIDA) Network registry identifying those with mucocutaneous Behçet’s disease (BD) may progres to major organ involvement (MOI)m especially at later stages.
buff.ly/7BatMxI
A New Disease Activity Score for Antiphospholipid Syndrome?
APS is a systemic autoimmune disorder. It is characterised by the presence of antiphospholipid antibodies and a broad spectrum of clinical features, causing obstetric as well as TMN symptoms.
buff.ly/o0GUN7b
APS is a systemic autoimmune disorder. It is characterised by the presence of antiphospholipid antibodies and a broad spectrum of clinical features, causing obstetric as well as TMN symptoms.
buff.ly/o0GUN7b
November 24, 2025 at 3:00 PM
A New Disease Activity Score for Antiphospholipid Syndrome?
APS is a systemic autoimmune disorder. It is characterised by the presence of antiphospholipid antibodies and a broad spectrum of clinical features, causing obstetric as well as TMN symptoms.
buff.ly/o0GUN7b
APS is a systemic autoimmune disorder. It is characterised by the presence of antiphospholipid antibodies and a broad spectrum of clinical features, causing obstetric as well as TMN symptoms.
buff.ly/o0GUN7b
In 2024, 77 pts referred to Rheum for possible PMR were ultimately Dx w/ B19 viral infx. 96% had arthralgia & 7% had PMR-like features (5/5 w/ BL shoulder/neck. prolonged AM stiff, fever & Hi CRP/ESR - none had hip pain. 4/5 were male, w/ mean age of 55 yrs. None were RF/CCP+ buff.ly/9oBF78e
November 23, 2025 at 7:00 PM
In 2024, 77 pts referred to Rheum for possible PMR were ultimately Dx w/ B19 viral infx. 96% had arthralgia & 7% had PMR-like features (5/5 w/ BL shoulder/neck. prolonged AM stiff, fever & Hi CRP/ESR - none had hip pain. 4/5 were male, w/ mean age of 55 yrs. None were RF/CCP+ buff.ly/9oBF78e
25-Hydroxyvitamin D levels and Lupus Outcomes
Lupus patients entering a prospective cohort study with low vitamin D levels faced doubled all-cause mortality risk and tripled risk for major cardiovascular events during follow-up averaging 6 years, researchers said.
buff.ly/P05kLYj
Lupus patients entering a prospective cohort study with low vitamin D levels faced doubled all-cause mortality risk and tripled risk for major cardiovascular events during follow-up averaging 6 years, researchers said.
buff.ly/P05kLYj
November 23, 2025 at 5:00 PM
25-Hydroxyvitamin D levels and Lupus Outcomes
Lupus patients entering a prospective cohort study with low vitamin D levels faced doubled all-cause mortality risk and tripled risk for major cardiovascular events during follow-up averaging 6 years, researchers said.
buff.ly/P05kLYj
Lupus patients entering a prospective cohort study with low vitamin D levels faced doubled all-cause mortality risk and tripled risk for major cardiovascular events during follow-up averaging 6 years, researchers said.
buff.ly/P05kLYj
PROSPERO meta-analysis shows an effect of diet on #RA risk. 8 independent studies (n=270,121) showed a reduced risk of incident RA with Anti-inflammatory (OR 0.56; 0.31–0.99), Mediterranean (OR 0.88; 0.78–0.99), and HEI (OR 0.60; 0.25–1.47), but not DASH diets buff.ly/lNp7m2U
November 22, 2025 at 7:00 PM
PROSPERO meta-analysis shows an effect of diet on #RA risk. 8 independent studies (n=270,121) showed a reduced risk of incident RA with Anti-inflammatory (OR 0.56; 0.31–0.99), Mediterranean (OR 0.88; 0.78–0.99), and HEI (OR 0.60; 0.25–1.47), but not DASH diets buff.ly/lNp7m2U
Retrospective cohort study adult RA patients shows that TRIPLE Positivity (RF + /ACPA + /ANA +) was consistently associated with higher disease activity at baseline and 12 months of follow-up and lower rates of sustained remission compared to RF + /ACPA + /ANA- buff.ly/yAZTea8
November 22, 2025 at 5:00 PM
Retrospective cohort study adult RA patients shows that TRIPLE Positivity (RF + /ACPA + /ANA +) was consistently associated with higher disease activity at baseline and 12 months of follow-up and lower rates of sustained remission compared to RF + /ACPA + /ANA- buff.ly/yAZTea8
Did you miss RheumNow Live 2025? 👀
Don’t make the same mistake twice.
🔥 RNL 2026 Early Bird Registration is LIVE — now through Dec 1.
Where clinical science meets real-world rheum talk.
🎟️ rheumnow.live
Don’t make the same mistake twice.
🔥 RNL 2026 Early Bird Registration is LIVE — now through Dec 1.
Where clinical science meets real-world rheum talk.
🎟️ rheumnow.live
November 22, 2025 at 3:00 PM
Did you miss RheumNow Live 2025? 👀
Don’t make the same mistake twice.
🔥 RNL 2026 Early Bird Registration is LIVE — now through Dec 1.
Where clinical science meets real-world rheum talk.
🎟️ rheumnow.live
Don’t make the same mistake twice.
🔥 RNL 2026 Early Bird Registration is LIVE — now through Dec 1.
Where clinical science meets real-world rheum talk.
🎟️ rheumnow.live
RheumNow Live 2026
Rheumatologists don’t just attend #RheumNowLive — they shape it.
Join the conversation that defines our field.
🕓 Early Bird registration open through 12/1
👉 rheumnow.live
#RheumTwitter #Rheumatology #CME #RNL2026 #MedTwitter #HCPcommunity
Rheumatologists don’t just attend #RheumNowLive — they shape it.
Join the conversation that defines our field.
🕓 Early Bird registration open through 12/1
👉 rheumnow.live
#RheumTwitter #Rheumatology #CME #RNL2026 #MedTwitter #HCPcommunity
November 21, 2025 at 12:00 AM
RheumNow Live 2026
Rheumatologists don’t just attend #RheumNowLive — they shape it.
Join the conversation that defines our field.
🕓 Early Bird registration open through 12/1
👉 rheumnow.live
#RheumTwitter #Rheumatology #CME #RNL2026 #MedTwitter #HCPcommunity
Rheumatologists don’t just attend #RheumNowLive — they shape it.
Join the conversation that defines our field.
🕓 Early Bird registration open through 12/1
👉 rheumnow.live
#RheumTwitter #Rheumatology #CME #RNL2026 #MedTwitter #HCPcommunity
APEX Study: Inhibition of structural damage progression with Guselkumab in PsA
Guselkumab, a human IL-23 inhibitor, was evaluated in patients with active PsA and shown to have both clinical and radiographic benefits at weeks 24 and 48.
rheumnow.com/news/apex-st...
Guselkumab, a human IL-23 inhibitor, was evaluated in patients with active PsA and shown to have both clinical and radiographic benefits at weeks 24 and 48.
rheumnow.com/news/apex-st...
November 20, 2025 at 8:00 PM
APEX Study: Inhibition of structural damage progression with Guselkumab in PsA
Guselkumab, a human IL-23 inhibitor, was evaluated in patients with active PsA and shown to have both clinical and radiographic benefits at weeks 24 and 48.
rheumnow.com/news/apex-st...
Guselkumab, a human IL-23 inhibitor, was evaluated in patients with active PsA and shown to have both clinical and radiographic benefits at weeks 24 and 48.
rheumnow.com/news/apex-st...
Rheumatology Supply and Demand (2009 - 2024)
A retrospective review of US rheumatology manpower and training from 2009- ‘24 shows that US rheumatology training has become competitive, with an increasing surplus of applicants compared to available training positions.
rheumnow.com/news/rheumat...
A retrospective review of US rheumatology manpower and training from 2009- ‘24 shows that US rheumatology training has become competitive, with an increasing surplus of applicants compared to available training positions.
rheumnow.com/news/rheumat...
November 20, 2025 at 7:01 PM
Rheumatology Supply and Demand (2009 - 2024)
A retrospective review of US rheumatology manpower and training from 2009- ‘24 shows that US rheumatology training has become competitive, with an increasing surplus of applicants compared to available training positions.
rheumnow.com/news/rheumat...
A retrospective review of US rheumatology manpower and training from 2009- ‘24 shows that US rheumatology training has become competitive, with an increasing surplus of applicants compared to available training positions.
rheumnow.com/news/rheumat...
November 20, 2025 at 3:02 PM
Treating During Pregnancy (11.14.2025) | RheumNow rheumnow.com/news/treatin...
November 18, 2025 at 4:01 PM
Treating During Pregnancy (11.14.2025) | RheumNow rheumnow.com/news/treatin...
RNL 25 Replay: Rheumatoid Arthritis
Enjoy these excerpts from the RNL 2025 meeting, and join us for RNL 2026 in Dallas, TX - registration is now open! Visit rheumnow.live for complete details
rheumnow.com/video/rnl-25...
Enjoy these excerpts from the RNL 2025 meeting, and join us for RNL 2026 in Dallas, TX - registration is now open! Visit rheumnow.live for complete details
rheumnow.com/video/rnl-25...
November 18, 2025 at 3:00 PM
RNL 25 Replay: Rheumatoid Arthritis
Enjoy these excerpts from the RNL 2025 meeting, and join us for RNL 2026 in Dallas, TX - registration is now open! Visit rheumnow.live for complete details
rheumnow.com/video/rnl-25...
Enjoy these excerpts from the RNL 2025 meeting, and join us for RNL 2026 in Dallas, TX - registration is now open! Visit rheumnow.live for complete details
rheumnow.com/video/rnl-25...
Can EMR Treatment Suggestions Improve Decision Making?
rheumnow.com/news/can-emr...
rheumnow.com/news/can-emr...
November 17, 2025 at 7:02 PM
Can EMR Treatment Suggestions Improve Decision Making?
rheumnow.com/news/can-emr...
rheumnow.com/news/can-emr...
Hospital Mortality in Dermatomyositis
A cohort study reveals that hospitalized patients with dermatomyositis have a higher in-hospital mortality rate in the presence of active rash, interstitial lung disease, and an elevated neutrophil-to-lymphocyte ratio at admission.
buff.ly/1xNMOVT
A cohort study reveals that hospitalized patients with dermatomyositis have a higher in-hospital mortality rate in the presence of active rash, interstitial lung disease, and an elevated neutrophil-to-lymphocyte ratio at admission.
buff.ly/1xNMOVT
November 17, 2025 at 5:02 PM
Hospital Mortality in Dermatomyositis
A cohort study reveals that hospitalized patients with dermatomyositis have a higher in-hospital mortality rate in the presence of active rash, interstitial lung disease, and an elevated neutrophil-to-lymphocyte ratio at admission.
buff.ly/1xNMOVT
A cohort study reveals that hospitalized patients with dermatomyositis have a higher in-hospital mortality rate in the presence of active rash, interstitial lung disease, and an elevated neutrophil-to-lymphocyte ratio at admission.
buff.ly/1xNMOVT
Beyond malignancy, look out for LICATS with CAR-T
CD19 CAR-T cell therapy gained prominence in 2022 with the publication of Prof Schett’s successful case series involving 5 patients with refractory SLE. This field has since seen rapid growth.
buff.ly/o8ThQ8W
CD19 CAR-T cell therapy gained prominence in 2022 with the publication of Prof Schett’s successful case series involving 5 patients with refractory SLE. This field has since seen rapid growth.
buff.ly/o8ThQ8W
November 17, 2025 at 3:03 PM
Beyond malignancy, look out for LICATS with CAR-T
CD19 CAR-T cell therapy gained prominence in 2022 with the publication of Prof Schett’s successful case series involving 5 patients with refractory SLE. This field has since seen rapid growth.
buff.ly/o8ThQ8W
CD19 CAR-T cell therapy gained prominence in 2022 with the publication of Prof Schett’s successful case series involving 5 patients with refractory SLE. This field has since seen rapid growth.
buff.ly/o8ThQ8W